Publicaciones (12) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

    ESMO Open

  2. Clarification of Definitions of Hyperprogressive Disease during Immunotherapy

    JAMA Oncology

  3. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  4. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

  5. Cutaneous squamous cell carcinoma presenting with facial paralysis: good response to Cemiplimab

    JDDG - Journal of the German Society of Dermatology

  6. Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168] (European Journal of Cancer (2020) 136 (159–168), (S0959804920303300), (10.1016/j.ejca.2020.06.003))

    European Journal of Cancer

  7. Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S1535610820304165), (10.1016/j.ccell.2020.08.005))

    Cancer Cell

  8. Erratum: Siglec-15 as an emerging target for next-generation cancer immunotherapy (Clinical Cancer Research (2021) 27 (680-688) DOI: 10.1158/1078-0432.CCR-19-2925)

    Clinical Cancer Research

  9. Giant port-site recurrence after laparoscopic-staging for endometrial cancer

    International Journal of Gynecological Cancer

  10. In response to Haas RL et al.

    Radiotherapy and Oncology

  11. Pursuing biomarkers research for a more efficient use of PARP inhibitors

    International Journal of Gynecological Cancer

  12. Response to Escande et al.: Magnetic guided brachytherapy: Time for non-pelvic cancer? Example from tongue brachytherapy [1]

    Radiotherapy and Oncology